InvestorsHub Logo
Post# of 253179
Next 10
Followers 47
Posts 4694
Boards Moderated 0
Alias Born 07/19/2006

Re: super_trades post# 199539

Saturday, 02/06/2016 9:37:14 AM

Saturday, February 06, 2016 9:37:14 AM

Post# of 253179
TRIL

The comment you reference is sufficiently vague that i am going to reserve judgement until i see data. TRIL has shown a tradeoff preclinically between efficacy and toxicity and went with the more active Fc in the clinic. stanford went with a weaker Fc to minimize toxicity. In this interview it seems clear the tox profile is even better than expected for the stanford drug, but if the TRIL data translates clinically it will be at the expense of efficacy, at least as monotherapy
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.